Vector Labs Ab04156-10.3 Anti-IL-5 [Sch 55700 (Reslizumab)], Human IgG1, Fc Silent™, kappa (100 μg) Centrifuge Bundle Savings at Sycamore Life Sciences

Description

Product Class: Purified
Clone ID: Sch 55700 (Reslizumab)
Heavy Chain Modification: Fc Silent™
Synonyms: IL5; Interleukin-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; CDP-835; CDP835; h39D10; JES1-39D10; SCH55700
Amount: 100 μg
Application Codes Clone: Block; Inhibit; Neutralize; Therapeutic
Shipping Temperature: Wet Ice
Buffer Composition: PBS with 0.02% Proclin 300.
Original Format: IgG4
Storage Temperature: Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement: This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement: This antibody recognizes and binds human interleukin-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. This antibody specifically recognizes amino acids 89–93 (ERRRV) of human IL-5 and is capable of blocking the binding of IL-5 with IL-5 receptor (PMID: 10590259).
Application Notes: This antibody is a humanized version of anti-IL5 rat antibody 39D10. The binding affinity of the original human IgG4 version of this antibody was measured using Biacore analysis and it was reported that this antibody bound human IL-5 with a Kd= 81pM (PMID: 7613159). This antibody was capable of inhibiting the binding of hIL-5 to Ba/F3 cells and IL5 induced proliferation of human erythroleukemic cell line TF-1 with an EC50 of 45pM. The in vivo activity of this antibody was studied in Ascaris responsive monkeys, and it was reported that this antibody inhibits eosinophilia in allergic animal models with an extended biological duration (PMID: 7613159). This antibody was active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in allergic guinea pigs. It was reported that this antibody did not cause immunosuppression in guinea pigs (PMID: 9698918). It also blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs. In allergic rabbits, this antibody blocks cutaneous eosinophilia. In allergic cynomolgus monkeys, a single dose of this antibody (0.3 mg/kg i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months (PMID: 10514907). A study was also conducted to determine the effect of this antibody in patients with severe persistent asthma (PMID: 12649124). Clinical trials were conducted with this antibody to reduce asthma exacerbations, control asthma-related symptoms and improve pulmonary function in patients with eosinophilic asthma (PMID: 26372797).

Product Class:	Purified
Clone ID:	Sch 55700 (Reslizumab)
Heavy Chain Modification:	Fc Silent™
Synonyms:	IL5; Interleukin-5; B-cell differentiation factor I; Eosinophil differentiation factor; T-cell replacing factor; TRF; CDP-835; CDP835; h39D10; JES1-39D10; SCH55700
Amount:	100 μg
Application Codes Clone:	Block; Inhibit; Neutralize; Therapeutic
Shipping Temperature:	Wet Ice
Buffer Composition:	PBS with 0.02% Proclin 300.
Original Format:	IgG4
Storage Temperature:	Store at 4⁰C for up to 3 months. For longer storage, aliquot and store at -20⁰C.
Chimeric Use Statement:	This reformatted human antibody was made using the variable domain sequences of the original Human IgG4 format, for improved compatibility with existing reagents, assays and techniques.
Specificity Statement:	This antibody recognizes and binds human interleukin-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. This antibody specifically recognizes amino acids 89–93 (ERRRV) of human IL-5 and is capable of blocking the binding of IL-5 with IL-5 receptor (PMID: 10590259).
Application Notes:	This antibody is a humanized version of anti-IL5 rat antibody 39D10. The binding affinity of the original human IgG4 version of this antibody was measured using Biacore analysis and it was reported that this antibody bound human IL-5 with a Kd= 81pM (PMID: 7613159). This antibody was capable of inhibiting the binding of hIL-5 to Ba/F3 cells and IL5 induced proliferation of human erythroleukemic cell line TF-1 with an EC50 of 45pM. The in vivo activity of this antibody was studied in Ascaris responsive monkeys, and it was reported that this antibody inhibits eosinophilia in allergic animal models with an extended biological duration (PMID: 7613159). This antibody was active against lung eosinophilia in allergic monkeys and mice and against pulmonary eosinophilia and airway hyperresponsiveness in allergic guinea pigs. It was reported that this antibody did not cause immunosuppression in guinea pigs (PMID: 9698918). It also blocks the pulmonary eosinophilia and neutrophilia caused by tracheal injection of hIL-5 in guinea pigs. In allergic rabbits, this antibody blocks cutaneous eosinophilia. In allergic cynomolgus monkeys, a single dose of this antibody (0.3 mg/kg i.v.) blocks the pulmonary eosinophilia caused by antigen challenge for up to six months (PMID: 10514907). A study was also conducted to determine the effect of this antibody in patients with severe persistent asthma (PMID: 12649124). Clinical trials were conducted with this antibody to reduce asthma exacerbations, control asthma-related symptoms and improve pulmonary function in patients with eosinophilic asthma (PMID: 26372797).

Specifications

More Information
Brand	Vector Labs
UNSPSC	12161500

Reviews